Lenovo Launches GPU Advanced Services to Help Boost AI Workload Performance by Up to 30%
30.9.2025 16:00:00 EEST | Business Wire | Press release
With GPU demand outpacing enterprise deployment capacity, Lenovo today launched GPU Advanced Services to help customers boost workload performance by up to 30% and accelerate AI adoption.1 Enterprises can achieve these gains through optimized GPU deployment and tuning delivered by Lenovo experts, based on internal performance evaluations. For businesses, that means faster time-to-market for AI innovation and reduced infrastructure costs by avoiding underutilized GPUs.
“Enterprises are moving rapidly to operationalize AI, but many still struggle with the complexity of GPU infrastructure deployment,” said Steven Dickens, CEO and Principal Analyst of HyperFRAME Research. “Lenovo’s approach addresses this challenge by helping IT teams deploy faster, optimize performance, and scale confidently, which is exactly what the market needs as AI use cases become mainstream.”
As AI adoption surges, enterprises need scalable GPU infrastructure to support high-performance workloads. Lenovo GPU Advanced Services provide guided support to help enterprises design, deploy, and operate GPU-based systems efficiently. Taking a services-first approach, Lenovo enables enterprises to maximize existing investments and scale AI without being locked into proprietary stacks.
"With certified experts and deep platform integration, Lenovo helps enterprises deploy GPU infrastructure faster and run workloads more reliably, reducing risk and unlocking the full potential of their AI investments,” said Linda Yao, VP and General Manager, Hybrid Cloud & AI Solutions, Lenovo.
GPU Advanced Services align with validated Lenovo Hybrid AI Advantage™ solutions such as the Lenovo Hybrid AI 285 platform, enabling scalable deployment from a single node to multi-nodes with customizable AI software stack and services. Designed for high-performance workloads such as generative AI, real-time video processing, and content creation, these services address critical gaps in in-house expertise, infrastructure complexity, and performance tuning.
GPU Advanced Services: Flexible Options for Every Stage
GPU Advanced Services includes three modular options that can be purchased individually or combined, giving enterprises access to Lenovo experts at the stage that best fits their GPU adoption journey and avoiding a one-size-fits-all bundle.
- GPU Plan & Design Services– For organizations just beginning their AI journey, this service provides workload assessment, solution sizing, technology selection, and architecture planning to establish the right foundation.
- GPU Implementation Services – For teams ready to deploy, Lenovo experts deliver architecture documentation, stack configuration, deployment guidance, and knowledge transfer so systems are set up correctly and efficiently.
- GPU Managed Services – For enterprises running production AI, this service delivers ongoing optimization, updates, and recovery support, including patching and compliance, across hybrid and on-premises GPU environments.
Enterprises can accelerate their AI journey with Lenovo AI Fast Start, rapidly identifying and validating use cases before scaling confidently into production with GPU Advanced Services.
Proven Impact in Key Industries
Lenovo GPU Advanced Services ease the load on IT teams by streamlining deployment and creating a faster, lower-risk path from pilot to production. The services are designed to address challenges common across industries where AI is transforming operations:
- Healthcare – AI-assisted diagnostics with real-time insights help improve the speed and accuracy of patient care.
- Automotive – Managed services can help optimize edge AI models that power autonomous and connected vehicle systems.
- Media and Entertainment – GPU tuning can enhance real-time rendering and content production workflows, enabling creators to deliver richer experiences more efficiently.
- Cirrascale Cloud Services – Cut GPU deployment time by more than 40% with Lenovo expertise, accelerating AI innovation across customer environments.
A Proven Track Record in High-Performance GPU Solutions
Lenovo GPU Advanced Services offer flexible engagement backed by proven expertise in optimizing GPU infrastructure for performance and scalability. Built on Lenovo ThinkSystem and High-Performance Compute platforms, these services sit on top of GPU-rich Lenovo systems, ensuring customers maximize their hardware investments without being locked into a single platform.
Lenovo also brings unmatched leadership in advanced computing, ranked the #1 supercomputer provider for seven consecutive years2, #1 in x86 server reliability, and among the top in security.3 This trusted foundation ensures enterprises can scale AI infrastructure with confidence.
Discover how Lenovo GPU Advanced Services can help enterprises simplify management and scale AI with confidence at: http://lenovo.com/us/en/Solutions/Hybrid_Cloud_Services/GPU_Advanced_Services.
About Lenovo
Lenovo is a US$69 billion revenue global technology powerhouse, ranked #196 in the Fortune Global 500, and serving millions of customers every day in 180 markets. Focused on a bold vision to deliver Smarter Technology for All, Lenovo has built on its success as the world’s largest PC company with a full-stack portfolio of AI-enabled, AI-ready, and AI-optimized devices (PCs, workstations, smartphones, tablets), infrastructure (server, storage, edge, high performance computing and software defined infrastructure), software, solutions, and services. Lenovo’s continued investment in world-changing innovation is building a more equitable, trustworthy, and smarter future for everyone, everywhere. Lenovo is listed on the Hong Kong stock exchange under Lenovo Group Limited (HKSE: 992) (ADR: LNVGY). To find out more visit https://www.lenovo.com, and read about the latest news via our StoryHub.
[1] Based on Lenovo internal performance evaluations of optimized GPU deployment and tuning.
[2] Supercomputing leadership — Lenovo remains the world’s #1 supercomputer provider by number of systems on the June 2025 TOP500 list. See TOP500 list statistics and vendor share; Lenovo also reiterated #1 status at ISC 2025.
[3] x86 server reliability & security — Independent ITIC studies report Lenovo ThinkSystem x86 servers with the best uptime for 11 straight years (latest report referenced February 2025) and among the most secure platforms in ITIC’s 2025 server security survey. See LenovoPress ITIC summary and coverage of the 2025 ITIC security survey; additional 2024 survey recap also confirms leadership.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250930144708/en/
Contacts
Zeno Group for Lenovo: lenovossg@zenogroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release
International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release
Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom